Clinical trials: Huntingtons Disease
Huntington Disease
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and…
- Trial name
- NCT06976983
- Testing
- Portable ergonomic helmet for real tSMS
- Volunteers
- 30 people
- Sponsor
- Neuromed IRCCS
Huntington Disease
Study of Biomarkers That Predict the Evolution of Huntington's Disease
Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder typically becoming noticeable in middle age.
- Trial name
- BIOHD (NCT01412125)
- Testing
- Huntington patient evaluation, Healthy subject evaluation
- Where
- France
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
Nilotinib in Huntington's Disease
Based on strong pre-clinical evidence of the effects of Nilotinib on neurodegenerative pathologies, including autophagic clearance of neurotoxic proteins, neurotransmitters (dopamine and glutamate), immunity and behavior, the…
- Trial name
- Tasigna HD (NCT03764215)
- Testing
- Nilotinib 150 MG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Georgetown University
Huntington Disease
31P-MRS and Huntington Disease
The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.
- Trial name
- PRO-MH (NCT01359774)
- Testing
- 31P-MR spectroscopy, 31P-RMN spectroscopy
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Huntington Disease
Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD
SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine…
- Trial name
- SHIELD HD (NCT04406636)
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 70 people
- Sponsor
- CHDI Foundation, Inc.
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Huntington Disease
Pilot Study of Minocycline in Huntington's Disease
This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD.
- Trial name
- NCT00277355
- Testing
- minocycline
- Where
- 12 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Merit Cudkowicz
Chorea, Huntington's Disease
Treatment of Huntington's Chorea With Amantadine
Huntington's disease is a chronic disorder passed on through genetic autosomal dominant inheritance. The condition usually begins between the ages of 30 and 50 years and it is characterized by involuntary movements in the face…
- Trial name
- NCT00001930
- Testing
- Amantadine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Huntington's Disease
Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease
This is a single centre, controlled phase I study, which evaluates safety and efficacy of stimulation of lower caudal two contacts (GPI) vs. upper cranial two contacts (GPE) in Huntington´s disease (HD).
- Trial name
- NCT00902889
- Testing
- Stimulation
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myotonic Dystrophy 1, Huntington Disease
NIPD on cffDNA for Triplet Repeat Diseases
The purprose of this study is to develop and validate an analytical NIPD test for triplet repeat disesases by NGS analysis from maternal blood, searching for the familial mutation in families at risk of having one of the…
- Conditions
- Myotonic Dystrophy 1, Huntington Disease, Fragile X Syndrome
- Trial name
- NCT04698551
- Testing
- Non invasive prenatal diagnosis
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Montpellier
Huntington Disease
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and…
- Trial name
- NCT03810898
- Testing
- Radioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease (HD)
Creatine Safety & Tolerability in Huntington's Disease
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
- Trial name
- CREST-X (NCT01412151)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
- Trial name
- NAC-preHD (NCT05509153)
- Testing
- NAC
- Where
- 5 sites in Australia
- Volunteers
- 160 people
- Sponsor
- Western Sydney Local Health District
Huntingtons Disease
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
- Trial name
- NCT03761849
- Testing
- RO7234292
- Where
- 96 sites in United States, Argentina and 16 more
- Volunteers
- 899 people
- Sponsor
- Hoffmann-La Roche
Huntingtons Disease
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response…
- Trial name
- NCT04000594
- Testing
- RO7234292 (RG6042)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Huntington Disease
Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients
Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric and quality of life battery of scales at baseline.
- Trial name
- NCT03417583
- Testing
- Protocol Intervention Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Huntington Disease
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.
- Trial name
- PRO-MH2 (NCT01696708)
- Testing
- 31-Phosphorus RMN Spectroscopy
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France